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ABSTRACT
Anemia, already common in cancer patients, is often
exacerbated by chemotherapy. Cancer patients who
are anemic have been shown to have a blunted re-
sponse for production of endogenous erythropoietin
growth factor. This anemia can be corrected with ex-
ogenous erythropoietin growth factors, of which
three available are worldwide: epoetin alfa, epoetin
beta, and darbepoetin alfa. Collectively, these drugs
are known as erythropoiesis-stimulating agents
(ESAs). Orders for ESAs have been used not only to
reverse anemia so as to avoid blood transfusion, but
also to improve quality of life. Guidelines have been
developed for initiation, dosage titration, and termi-
nation of these agents. Since the late 1990s, trials
have been conducted using ESAs in unapproved dos-
ing regimens or to reach hemoglobin levels outside
of approved guidelines, raising several safety con-
cerns. The present article explores the risks and ben-
efits of ESAs.
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1. INTRODUCTION
Anemia is a common finding in cancer patients and
can be a result of treatment or of underlying dis-
ease 1. A large-scale audit of blood transfusions in
2719 cancer patients showed that 38% had a hemo-
globin level below 11.0 g/dL during chemotherapy
and that 33% of the patients required at least one
blood transfusion 2.
Recombinant human erythropoietin was first used
clinically in renal dialysis patients in the 1980s, at
which time it was shown to correct anemia in end-
stage renal disease 3. Those findings led to a recogni-
tion that anemia in patients with malignancy might
also be able to be reversed, leading to an improve-
ment in hemoglobin level, rate of transfusion, and
quality of life (QOL).
The first randomized trial in cancer patients dem-
onstrated that recombinant human erythropoietin is
effective for treating anemia in cancer patients on che-
motherapy 4. Three large, open, nonrandomized tri-
als confirmed that finding and, more importantly,
established that the highest incremental improvement
in QOL was achieved at an optimum hemoglobin level
of 12 g/dL 5–7. That level of 12 g/dL is now consid-
ered the accepted level by various guidelines com-
mittees, including those of the American Society of
Hematology 8, the American Society of Clinical On-
cology 9, and the National Comprehensive Cancer
Network 10. (The 12 g/dL level will be important to
remember in the exploration of publications report-
ing negative safety and survival in the remainder of
the present article.)
After the open-label studies, a randomized pla-
cebo-controlled study by Littlewood et al. 11 con-
firmed the relationship between anemia, fatigue, and
QOL. A retrospective review in that trial suggested a
survival advantage in patients treated with epoetin
alfa. That finding led to prospective trials that at-
tempted to validate the better-survival hypothesis. To
strengthen the argument, higher-than-normal hemo-
globin levels were defined for achievement. As well,
to broaden the indications for use, trials were con-
ducted in patients not on active chemotherapy treat-
ment. Neither of those strategies worked, and
confusion regarding the safety of this class of drugs
instead resulted. To complicate the data even more,
the media have been emphasizing the profit margins
of the pharmaceutical companies managing the drugs.
The aim of the present article is to critically re-
view the benefits and risks associated with the use of
erythropoiesis-stimulating agents (ESAs) as support-
ive care in cancer patients. Demonstrated benefits of
ESAs include lower rates of transfusion and improved
QOL, including reduced fatigue and better cognition.
Demonstrated risks of ESAs include risk of throm-
boembolic disease, negative impact on survival, and
risk of tumour proliferation.
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2. BENEFITS
2.1 Lower Rates of Transfusion
Two ESAs, epoetin alfa (Eprex: Janssen–Ortho, Tor-
onto, ON) and darbepoetin alfa (Aranesp: Amgen,
Thousand Oaks, CA, U.S.A.) are approved in Canada.
The basis for this approval by the Health Protection
Branch of Health Canada and the U.S. Food and Drug
Administration (FDA) was a proven reduction (as com-
pared with placebo) in the proportion of patients trans-
fused during chemotherapy.
Six randomized placebo-controlled double-blind
clinical trials using epoetin alfa were pooled 12. Ane-
mic cancer patients (n = 131) who were to receive at
least 12 weeks of concurrent chemotherapy were ran-
domized (1:1) to receive epoetin alfa 150 U/kg or pla-
cebo subcutaneously three times weekly for
12 weeks. Half of the patients received cisplatin-con-
taining chemotherapy regimens. Efficacy results
showed a reduction in transfusions by approximately
50% during the second and third months of chemo-
therapy in the patients treated with epoetin alfa. Table I
summarizes the results.
Approval of darbepoetin alfa for the treatment of
anemia in cancer patients on chemotherapy was also
based on a proven reduction in transfusions. A phase III
double-blind placebo-controlled randomized (1:1) study
of darbepoetin alfa was preformed in anemic patients
with untreated non-small-cell or small-cell lung can-
cer who were to receive at least 12 weeks of platinum-
containing chemotherapy 13. A total of 314 patients were
randomized to darbepoetin alfa 2.25 mg/kg or placebo
subcutaneously weekly. Patients were stratified by tu-
mour type. As in the epoetin alfa trial, efficacy results
for treatment with darbepoetin alfa showed an approxi-
mately 50% reduction in transfusions, a result that was
significant from week 5 through the end of treatment.
Table II summarizes the results.
The risks of blood transfusion must be under-
stood. The most common serious risk of red cell trans-
fusion is transfusion-related acute lung injury. The
risk of this complication is estimated to be 1 in 432
whole-blood units to 1 in 557,000 red-blood-cell
units 14. The risk of infection with human blood prod-
ucts changes with time and has improved since the
late 1990s because of the application of careful
screening techniques for antibodies against HIV,
hepatitis B and C, and West Nile virus. In 1991, the
risk of HIV was 1 in 493,000; in 2003, it was esti-
mated at less than 1 in 1,000,000 15. But it is the un-
known bacterium or virus that cannot be uncovered
through testing. For that reason, the Kreever Com-
mission recommended that “the operator of the blood
supply system promote appropriate use of, and alter-
natives to, blood components and blood products.
Blood components and blood products will never be
without risk. The best way to reduce that risk is to
reduce their use” 16. For liability reasons, hospital
authorities ask doctors and their patients to sign con-
sent forms acknowledging that the patient understands
the risk of such procedures. It would be short-sighted
and naïve to believe that another infectious agent will
never be seen in human blood products.
In summary, ESAs are efficacious in reducing the
need for blood transfusions in cancer patients on che-
motherapy. Across several studies, approximately
50% of patients on chemotherapy without ESAs re-
quired transfusions, as compared with 20% of pa-
tients receiving ESAs while on chemotherapy. Blood
transfusions have a fairly high-safety profile, but the
risk of infectious components continues to be a con-
cern. The risk is always evolving as new infectious
agents are found within human donor products. The
risk of blood transfusions must constantly be weighed
against their benefit.
2.2 Improvement in QOL
Other than minimizing the need for blood transfusions,
one of the main reasons that physicians order ESAs for
their patients on chemotherapy is to achieve an im-
provement in QOL. As duration of survival increases,
QOL is increasingly being perceived as an important
goal in the management of cancer. Symptoms of ane-
mia include dyspnea, weakness, tachycardia, impaired
cognition, depression, and fatigue. It is understand-
able how all of those symptoms may lead to dimin-
ished QOL and how avoidance of anemia and
subsequent symptoms may lead to improved QOL.
When epoetin alfa and darbepoetin alfa were ap-
proved in Canada and the United States, they were
approved for their statistically significant reduction
in the requirement for transfusions. They did not meet
criteria set out by the U.S. FDA for approval for the
TABLE I Proportion of patients on epoetin alfa (EPO) transfused
during chemotherapy
Chemotherapy Patients transfused (%)
regimen On study During months 2 and 3
EPO Placebo EPO Placebo
Without cisplatin 44 44 21 33
With cisplatin 50 63 23 56
p < 0.05
Combined 47 53 22 43
p < 0.05
TABLE II Proportion of patients on darbepoetin alfa transfused dur-
ing chemotherapy
Period Patients transfused
Darbepoetin alfa Placebo
(n)( % ) ( n) (%)
Week 5 to end of treatment 31 27 77 52
(N=148) (N=149)BENEFITS AND RISKS OF ESAs IN CANCER
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indication of QOL improvement. Those FDA criteria
are extensive, and they include 17
• use of validated instruments;
• double-blinding of personnel administering the
QOL questionnaires;
• prospective identification of key outcomes, criti-
cal time points, and minimum differences in
scores to be considered clinically significant; and
• a detailed plan for preventing missing data, in-
vestigating the pattern of missing data, and ad-
dressing missing data in the analysis.
Although not meeting the foregoing criteria, mul-
tiple trials have reported a positive correlation between
ESA use and improvement in QOL. The strongest evi-
dence comes from a randomized controlled trial by
Littlewood et al. 11. That trial enrolled 375 patients
with a mean baseline hemoglobin of 10 g/dL. Of the
375 patients, 335 were evaluable for QOL outcomes,
which were evaluated using the Functional Assess-
ment of Cancer Therapy–Anemia (FACT-AN) instrument
and the Linear Analogue Self-Assessment (LASA)
scales. Positive, statistically significant differences
between the ESA-treated and untreated groups were
found. Results from the Medical Outcomes Study
Short Form–36 (SF–36) showed a trend in the same
direction, but did not reach significance (Table III).
Criticism of the trial focused on missing descriptions
of the key methodologic features for administering
the QOL instruments. As well, the study did not pro-
spectively define the minimum changes in QOL score
that would be considered clinically significant.
Although not meeting FDA requirements, three
large community-based nonrandomized open-label
studies performed with epoetin alfa can still provide
insights. Those studies enrolled a total of 7724 pa-
tients, of whom 7283 were assessable. Epoetin alfa
was administered to anemic patients with non-
myeloid malignancies undergoing standard chemo-
therapy. Glaspy et al. 5 and Demetri et al. 6 used
3-times-weekly dosing, and the third study by
Gabrilove et al. 7 used once-weekly dosing. Measures
of  QOL included the FACT-General, the FACT-AN
subscale, and the LASA. The validated cancer-specific
LASA instrument, which is used to assess therapy-
related QOL, measures the QOL parameters of Energy
Level, Ability to Do Daily Activities, and Overall
QOL. In each of the three studies, the scores for the
latter three items were significantly (p < 0.001) im-
proved from baseline (Table IV). In the study by Glaspy
and colleagues 5, increases in hemoglobin level were
correlated with the improvements for each of the QOL
parameters independent of tumour response, and in
the study by Demetri and colleagues 6, similar corre-
lations were evident in patients having a complete re-
sponse, a partial response, or stable disease.
Finally, the most recent Cochrane analysis in-
cluded a systematic review of 9353 cancer patients
enrolled into randomized controlled trials of epoetin
alfa, epoetin beta, or darbepoetin alfa, updating the
evidence to include trials from 1985 to 2005 18. The
authors concluded that the results show an overall
positive effect of epoetin on QOL that seems unlikely
to be attributable to chance.
2.3 Improvement in Cognition
The central nervous system has been demonstrated
to contain epoetin receptors and to produce epoetin.
Epoetin has been hypothesized to possibly protect
neurons from injury such as ischemia, trauma, epi-
lepsy, Parkinson disease, and disturbances of cogni-
tive function 19. The ability of ESAs to improve
cognition was demonstrated by O’Shaughnessy
et al. 20 in women with breast cancer undergoing ad-
juvant chemotherapy. That study was followed by a
randomized double-blind placebo-controlled trial to
prospectively evaluate the effects of ESAs on several
factors (cognitive function, mood, asthenia, and
QOL) 21. Patients were randomized to receive
40,000 IU of subcutaneous epoetin alfa or placebo
every week during 4 cycles of chemotherapy over
3 months. Interim results indicated that the use of
ESA improved hemoglobin and asthenia, reduced QOL
decline, improved mood, and may have ameliorated
cognitive function. Because of the small sample size,
the results for cognitive function were not statisti-
TABLE III Quality of life (QOL) outcomes in Littlewood et al. 11
Treatment Evaluable for Overall QOL Energy level Daily activities Other QOL Other QOL
arm Transfusion (n) QOL (n) % Change p Value % Change p Value % Change p Value measure % Change p Value
Control 115 108 NA –5.8 –6.0
Epoetin 244 227 NA <0.01 7.8 <0.001 7.3 <0.01
Control 115 90 FACT-AN: anemia –9.4
Epoetin 244 200 FACT-AN: anemia 14.4 <0.01
Control 115 90 FACT-AN: fatigue –4.2
Epoetin 244 200 FACT-AN: fatigue 5.7 <0.01
Control 115 NA SF-36 NA
Epoetin 244 NA SF-36 NA NS
NA = not available; FACT-AN = Functional Assessment of Cancer Therapy–Anemia; SF-36 = Medical Outcomes Study Short Form–36.MELOSKY
S13
CURRENT ONCOLOGY—VOLUME 15, SUPPLEMENT 1
cally significant; they remain hypothesis-generating
only.
3. RISKS
3.1 Increased Risk of Thrombosis
A significant side effect of drugs classified as ESAs is
an increased risk of thromboembolic events. The re-
cently published Cochrane meta-analysis included 9353
cancer patients enrolled from 1985 to 2005 into 57 ran-
domized placebo-controlled trials using epoetin alfa,
epoetin beta, or darbepoetin alfa 18. Treatment with an
ESA increased the risk of thromboembolic events [rela-
tive risk: 1.67; 95% confidence interval (CI): 1.35 to
2.06]. This risk increased proportionately as target he-
moglobin rose. The causation of thromboembolic events
in patients receiving erythropoietin growth factors is
complex because of the increased baseline risk of
thrombosis associated with chemotherapy and with
cancer in general. Accepted guidelines must be adhered
to, and careful follow-up of patients is mandatory.
3.2 Survival Analysis
With regard to survival, two early studies questioned a
survival benefit for ESAs given to cancer patients. More
recently, two additional trials demonstrated a negative
effect on overall survival. These four negative trials
that resulted in shorter survival deserve discussion.
The Breast Cancer Erythropoietin Survival Trial
(BEST) 22 was a randomized trial in metastatic breast
cancer. Patients who were not anemic received epo-
etin alfa or placebo, aiming to achieve a hemoglobin
level of 12–14 g/dL. Decreased survival at 1 year
[hazard ratio (HR): 1.35] was seen in the group treated
with epoetin alfa, with most of the deaths occurring
in the first 4 months, possibly secondary to throm-
botic cardiac vascular events. The aim for higher-
than-standard hemoglobin levels may explain this
result and is now discouraged.
The ENHANCE trial 23 was a study in patients with
head-and-neck cancer randomized to either placebo
or epoetin beta to achieve hemoglobin levels of 14.5–
15 g/dL. Patients were not anemic, and they received
radiation, but not chemotherapy. Again, a decrease
in survival (HR: 1.39) was seen in the ESA-treated
group, who, like the BEST trial patients, were being
treated to reach above-standard hemoglobin levels.
The EPO-CAN 20 trial 24 was a randomized trial in
non-small-cell lung cancer patients who were ane-
mic. Patients studied were not on active treatment
with either high-dose thoracic radiation or platinum-
based chemotherapy. Because an increase in the risk
of thrombosis was being recognized as feature of ESAs,
an unplanned safety analysis was performed after 70
patients had been randomized. The median survival
favoured the patients on the placebo arm (HR: 1.84),
and the study closed. Given the early high mortality
and the extremely small sample size, drawing any
conclusions was hard. The application of the trial was
also questioned, because ESA use in cancer patients
not on active treatment is not common practice.
Finally, Amgen 20010103 was a randomized trial
of darbepoetin alfa in cancer patients who were ane-
mic and, as in EPO-CAN 20, not on active cancer
therapy. Results were reported in letter format only
in The Cancer Letter 25. The primary endpoint, re-
duction in transfusion, was not met, and an increase
in mortality (HR: 1.30) was seen in the ESA arm. The
dosing regimen was not consistent with the approved
darbepoetin alfa product monograph. Follow-up was
only 4.3 months, and further follow-up and analysis
will be ongoing. As was seen in EPO-CAN 20, the use
of ESAs in patients not on active treatment is not com-
mon practice and is now discouraged.
In summary, of the four negative survival trials,
the first two treated patients so as to reach higher-
than-standard hemoglobin levels, and the second two
were conducted in cancer patients not on active treat-
ment. All four were studying ESAs outside of the stan-
dard guidelines and indications.
Multiple randomized trials have been published
showing no survival disadvantage with the use of
ESAs. Most recently, in large randomized trials of lung
cancer patients receiving chemotherapy, early ver-
sus late intervention with epoetin alfa 26 and a pla-
cebo-controlled comparison of darbepoetin 13
revealed no survival decrement. A randomized
double-blind placebo-controlled trial of epoetin alfa
in treatment of patients with small-cell lung cancer
was published in the Journal of Clinical Oncology in
2005 27. That study also closed prematurely, not be-
cause of safety concerns, but because of low accrual.
Baseline hemoglobin values were 12.8 g/dL and
13 g/dL in the two groups at the time of initiation of
treatment. The primary endpoint—overall tumour re-
sponse—was not significantly different at 72% for
TABLE IV Quality of life (QOL) outcomes a in community-based studies
QOL parameter Mean change in LASA score from baseline [mm (%)]
Glaspy et al., 1997 5 (n=1498) Demetri et al., 1998 6 (n=1749) Gabrilove et al., 2001 7 (n=2258)
Energy level 15.0 (38) 11.5 (29) 11.9 (30)
Ability in daily activities 13.9 (32) 11.2 (28) 10.8 (27)
Overall qol 11.0 (24) 9.8 (21) 9.3 (20)
a All results in this table: p < 0.01 versus baseline.BENEFITS AND RISKS OF ESAs IN CANCER
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the epoetin alfa group and 67% for placebo. Hemo-
globin was stable in the epoetin alfa group and de-
creased in the placebo group. Even though treatment
with epoetin alfa was outside the current guidelines,
survival in both groups was similar.
In terms of survival, the first Cochrane analysis
reported inconclusive evidence that erythropoietin
may improve overall survival (HR: 0.81; 95% CI: 0.67
to 0.99). Trials through December 2001 were included.
The more recent analysis that incorporated trials up
to 2005 included the BEST, ENHANCE, and EPO-CAN 20
studies. This latter analysis resulted in a hazard ratio
of 1.08 (95% CI: 0.99 to 1.18). The authors concluded
that there was uncertainty regarding “whether and how
epoetin or darbepoetin effects overall survival” 18.
3.3 Tumour Progression
Finally, tumour progression secondary to activation of
erythropoietin receptors has been questioned 28. Both
BEST and ENHANCE showed decreased tumour control, but
as discussed earlier, both used unapproved dosing regi-
mens. A third study deserves mention. The DAHANCA
trial 29 followed the ENHANCE study and was designed to
avoid the numerous protocol violations in ENHANCE and
subsequent difficulty in interpreting the results. As a
prospective trial in head-and-neck squamous cell carci-
noma in patients who were undergoing treatment with
definitive radiotherapy, DAHANCA planned to randomize
600 patients to darbepoetin alfa or placebo. Its primary
objective was the 5-year locoregional control rate. An
interim analysis in 484 patients demonstrated a 10% in-
crease in the locoregional failure rate among patients
treated with darbepoetin alfa (p = 0.01). Overall sur-
vival was not significantly different, but did trend to-
ward shorter survival in the ESA arm (p = 0.08). This
study had many limitations. The dosing regimen and
dose adjustment rules for darbepoetin alfa were not ap-
proved. The target hemoglobin was 14–15.5 g/dL. As
well, the design of the study was not adequate to assess
tumour proliferation, because no uniform imaging as-
sessment was conducted at baseline or at recurrence,
nor was proliferation confirmed by biopsy. To further
complicate the interpretation of study results, patients
were treated with a hypoxic radiosensitizer, nimorazole,
which is not routine practice. Moreover, nimorazole has
not been studied for safety when given in combination
with ESAs 30. The final study analysis will be reported to
the FDA in late 2008.
The relationship between the presence of eryth-
ropoietin receptors and tumour proliferation attrib-
utable to exogenous erythropoietin with the use of
ESAs has not been established. Outside of simple pres-
ence, the function of erythropoietin receptors is not
well understood. In vitro studies vary in their con-
clusions. If erythropoietin has a direct effect on tu-
mour cell growth, then cancer cells must express
functional erythropoietin receptors or protein on their
surface. The commercial antibody used to detect such
receptors is Santa-Cruz C-20. This antibody lacks
specificity and cannot distinguish cell-surface expres-
sion from intracellular expression 31. The results of
further studies must be awaited.
In summary, the risk of thrombosis and embolism
is definitely increased with the use of ESAs. Careful
monitoring of hemoglobin levels in patients is man-
datory. The negative survival studies are difficult to
interpret because of target hemoglobin levels higher
than those recommended, poor study design, and en-
rolment of patients not on active care. The trials show-
ing tumour progression suffer from similar limitations.
4. SUMMARY
Cancer-related anemia impairs patient functioning
through a variety of direct and indirect mechanisms.
A large body of evidence demonstrates that treatment
with ESAs of anemia in cancer patients on active che-
motherapy significantly increases hemoglobin lev-
els, reduces the requirement for transfusions, and
improves QOL. In addition, gains in cognitive func-
tion are hypothesized.
Risks are also associated with ESAs: Safety issues
include increased thromboembolic risk. As well, four
studies show decreased survival and three studies
suggest tumour proliferation with the use of ESAs. All
of these findings are limited, because all of the stud-
ies used unapproved dosing regimens or aimed for
hemoglobin levels higher than generally recom-
mended. Attention to the target hemoglobin of
12 g/dL must be emphasized. Adherence to guide-
lines concerning ESAs in the management of cancer
patients on active treatment should be mandatory.
In May 2004, the FDA’s Oncologic Drugs Advi-
sory Committee (ODAC) revised product labelling to
include warnings against maintaining hemoglobin
levels above 12 g/dL. Given the decreased survival
seen in the Amgen 20010103 study discussed ear-
lier, the ODAC met again in May 2007. “Black box”
warnings were initiated in both Canada and the United
States. The panel voted to have Amgen and Johnson
& Johnson further strengthen the warning labels of
their ESAs and carry out additional safety studies on
the drugs. A final report from the FDA is still pending.
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